Central nervous system autoimmune diseases associated with COVID-19: Comprehensive review
Journal Title: Neurology Letters - Year 2022, Vol 1, Issue 2
Abstract
The first appearance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) named coronavirus disease 2019 (COVID-19) was reported from Wuhan in December 2019. While this virus displays several respiratory manifestations such as severe pneumonia and acute respiratory distress syndrome, there are several reports of nervous system involvement in the affected patients. Currently, there is a growing number of cases with central nervous system (CNS) autoimmune diseases (ADs) including autoimmune encephalitis (AE), neuromyelitis optica spectrum disorder (NMOSD), CNS vasculitis, acute disseminated encephalomyelitis (ADEM), and multiple sclerosis (MS) secondary to COVID-19 infection. Symptoms of these diseases vary from mainly drowsiness, delirium, and motor deficits in ADEM, MS, and AE and also visual impairment, and sensory problems in NMOSD and transverse myelitis patients. The severity of COVID-19 symptoms was also different from disease to disease. Based on the previous studies moderate corticosteroid therapy or other medication such as intravenous human immunoglobulins (IVIG), and plasma exchange (PLEX) is suggested for the treatment of CNS ADs in COVID patients. Also, patients with a previous history of ADs and other comorbidities such as hypertension, diabetes mellitus, hypercholesterolemia, and ischemic heart disease are at greater risk to develop severe complications of COVID compared to other patients. Current pieces of evidence demonstrated that CNS ADs can occur due to COVID-19 infection and the healthcare system should attention to CNS ADs as a complication of COVID-19. However, further investigations are strongly needed to confirm these findings.
Authors and Affiliations
Fardin Nabizadeh, Kasra Pirahesh, Fatemeh Sodeifian, Seyedeh Melika Hashemi, Mohammad Balabandian, Nasim Rezaeimanesh, Abdorreza Naser Moghadasi
Keywords
Related Articles
- EP ID EP711703
- DOI 10.52547/NL.1.2.69
- Views 80
- Downloads 0
Biomaterials in The Treatment of Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS) is a progressively debilitating disease characterized by selective neurodegeneration of upper motor neurons in the brain and lower motor neurons in the brainstem and spinal cord. Degen...
Antioxidant supplements and cognition in Multiple Sclerosis: a systematic review
Background: Cognitive dysfunction is a debilitating characteristic of multiple sclerosis (MS) that affects approximately 60% of patients. To date, the only effective treatments for cognitive decline are cognitive rehabil...
Neurology Letters is born!
On behalf of our editorial board, editorial team, authors, reviewers, and supporting institutions – we warmly welcome you to the first issue of the Neurology Letters. This is the official journal of the Neurology departm...
Role of Biomaterials in treatment of Alzheimer’s disease: A literature review
Currently, five medications have been approved by the FDA to treat Alzheimer's disease (AD); Donepezil, which is used at all stages of AD, galantamine, and rivastigmine for mild to moderate stages, and Memantine and a co...
Acute relapse of Multiple Sclerosis (MS) in an adolescent patient after Tuberculin skin test (TST): a case report
Activation of MS as a result of bacterial and viral infections is proposed by various studies. However, immune responses initiated by a bacterial antigen can rarely lead to the activation or occurrence of MS. Hereby, we...